Search alternatives:
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
Showing 41 - 60 results of 65,338 for search '(( 5 ((nm decrease) OR (a decrease)) ) OR ( 5 ((w decrease) OR (mean decrease)) ))', query time: 0.92s Refine Results
  1. 41
    Comparison of wind roses between ERA5 reanalysis and in-situ measured data. a: W03 station, b: W08 station, c: W13 station and d: W19 station.

    Comparison of wind roses between ERA5 reanalysis and in-situ measured data. a: W03 station, b: W08 station, c: W13 station and d: W19 station. by Weidong Ji (129916)

    Published 2025
    Save to List
    Saved in:
  2. 42
    Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation.

    Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation. by Juanita K. Hodax (6848540)

    Published 2019
    Save to List
    Saved in:
  3. 43
    Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol.

    Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol. by Kaley M. Wilburn (12060476)

    Published 2022
    Save to List
    Saved in:
  4. 44
    Tax expression is associated with decreased cellular motility.

    Tax expression is associated with decreased cellular motility. by Saumya Ramanayake (7879091)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 45
    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W19 station).

    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

    Published 2025
    Save to List
    Saved in:
  6. 46
    TREM1 inhibition decreases HIV mediated inflammatory cytokine production.

    TREM1 inhibition decreases HIV mediated inflammatory cytokine production. by Jinhee Hyun (6900683)

    Published 2019
    Save to List
    Saved in:
  7. 47
    S5 Fig -

    S5 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Save to List
    Saved in:
  8. 48
    Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR.

    Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR. by Jordan A. Gunning (18143970)

    Published 2024
    Save to List
    Saved in:
  9. 49
    Ce6 decreases the amount of TMV PQS5 upon photo-irradiation.

    Ce6 decreases the amount of TMV PQS5 upon photo-irradiation. by Congbao Xie (17599247)

    Published 2023
    Save to List
    Saved in:
  10. 50
    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial

    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

    Published 2020
    Save to List
    Saved in:
  11. 51
    Impaired Ubr5 function results in increased canonical and decreased non-canonical HH signalling.

    Impaired Ubr5 function results in increased canonical and decreased non-canonical HH signalling. by David Mellis (2833469)

    Published 2021
    Save to List
    Saved in:
  12. 52
    The spectral sensitivity of European seabass fed a 5% taurine diet.

    The spectral sensitivity of European seabass fed a 5% taurine diet. by Richard W. Brill (2337940)

    Published 2019
    Save to List
    Saved in:
  13. 53
    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG.

    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

    Published 2024
    Save to List
    Saved in:
  14. 54
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 55
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 56
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 57
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 58
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 59
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 60
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: